Inotersen treatment for patients with Hereditary transthyretin amyloidosis

Keyphrases

• Transthyretin Amyloidosis 100%
• Inotersen 100%
• Transthyretin 40%
• Thrombocytopenia 30%
• In(III) 20%
• Confidence Interval 20%
• Placebo Groups 20%
• Placebo 20%
• Glomerulonephritis 20%
• High-score 20%
• Diabetic Neuropathy 20%
• Norfolk Quality of Life 20%
• Quality of Life 10%
• Disease Stage 10%
• Serious Adverse Events 10%
• Misfolding 10%
• Placebo-controlled 10%
• Change from Baseline 10%
• Randomized Double-blind 10%
• Subcutaneous Injection 10%
• Poor Function 10%
• Phase II Trial 10%
• Neurological Diseases 10%
• Mutation Type 10%
• Clinically Significant Change 10%
• Antisense Oligonucleotides 10%
• Cardiomyopathy 10%
• One Dose 10%
• Least Mean Square 10%
• Multiple Organ Dysfunction 10%
• Poor Quality of Life 10%
• Efficacy Assessment 10%
• Single nucleotide Variant 10%
• Neuropathy Disability Score 10%
• Amyloid Accumulation 10%

Medicine and Dentistry

• ATTR Amyloidosis 100%
• Inotersen 100%
• Placebo 50%
• Quality of Life 40%
• Transthyretin 40%
• Thrombocytopenia 30%
• Glomerulonephritis 20%
• Amyloid Protein 20%
• Diabetic Neuropathy 20%
• Adverse Event 10%
• Neurologic Disease 10%
• Single Nucleotide Polymorphism 10%
• Neuropathy 10%
• Subcutaneous Injection 10%
• Antisense Oligonucleotide 10%
• Myocardial Disease 10%
• Efficacy Assessment 10%
• Polyneuropathy 10%
• Alginic Acid 10%
• Diseases 10%
• Least Squares Method 10%
• Organ Dysfunction 10%

Pharmacology, Toxicology and Pharmaceutical Science

• ATTR Amyloidosis 100%
• Inotersen 100%
• Placebo 50%
• Transthyretin 40%
• Thrombocytopenia 30%
• Glomerulonephritis 20%
• Diabetic Neuropathy 20%
• Amyloid Protein 20%
• Adverse Event 10%
• Neurologic Disease 10%
• Subcutaneous Injection 10%
• Neuropathy 10%
• Antisense Oligonucleotide 10%
• Polyneuropathy 10%
• Efficacy Assessment 10%
• Myocardial Disease 10%
• Alginic Acid 10%
• Diseases 10%